The Life Sciences team advised Fulcrum Therapeutics, Inc. (Nasdaq: FULC) on its underwritten public offering of 11,029,410 shares of its common stock at a public offering price of $7.82 per share, which included the full exercise of the underwriters’ option to purchase up to 1,438,618 additional shares. The gross proceeds were approximately $86.2 million before deducting underwriting discounts and other offering expenses. The offering closed on August 18, 2022 and the option closing occurred on August 23, 2022.
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Its most advanced product candidate, losmapimod, is in development to treat the root cause of facioscapulohumeral muscular dystrophy, or FSHD. Its other clinical product candidate is FTX-6058, which is being developed for the treatment of certain hemoglobinopathies, including sickle cell disease, or SCD.
The Goodwin team was led by Mitch Bloom, Marianne Sarrazin, Della Fok, Jen So and Dan Liu (Corporate), Theresa Kavanaugh and Gregory Gutierrez (Intellectual Property), Susan Lee and Dan Karelitz (Tax) and Ettore Santucci (Opinions).
For more details, read the press release and article in Markets Insider.